Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 6,765,001
Executive Summary
U.S. Patent 6,765,001, granted on July 20, 2004, to Eli Lilly and Company, covers an innovative antibody-based therapeutic approach targeting the human Interleukin-4 receptor alpha chain (IL-4Rα). This patent is significant within the biologic therapeutics sector, especially for conditions such as allergic asthma, atopic dermatitis, and other inflammatory disorders. The scope encapsulates novel monoclonal antibodies with specific binding characteristics, diagnostic uses, and therapeutic applications. Its patent claims are structured to maximize coverage of antibody compositions, methods of treatment, diagnostic assays, and pharmaceutical formulations. The patent landscape surrounding it is diverse, with notable overlaps with other cytokine-targeted biologics and antibody patents, fostering a competitive environment.
Scope and Claims of U.S. Patent 6,765,001
1. Overview of the Patent
The patent principally concerns an antibody or antibody fragment directed against human IL-4 receptor alpha chain (IL-4Rα), with implications for diagnosing and treating immune-mediated diseases. It establishes compositions comprising monoclonal antibodies with specific epitopes on IL-4Rα, methods of producing these antibodies, and their use in disease modulation.
Patent Classification
- International Patent Classification (IPC): A61K 39/12 (Medicinal preparations containing antibodies), C07K 16/00 (Immunoglobulins)
- Cooperative Patent Classification (CPC): A61K 39/00, C07K 16/00, A61P 37/00 (Antiallergic agents)
2. Key Patent Claims
The claims define the legal scope of the patent, categorized into several groups:
| Claim Type |
Main Focus |
Number of Claims (Approximate) |
| Composition Claims |
Monoclonal antibodies targeting IL-4Rα |
10–15 |
| Method Claims |
Methods of diagnosing or treating diseases using the antibodies |
8–12 |
| Production/Preparation Claims |
Processes for preparing the antibodies |
4–6 |
| Use Claims |
Use of antibodies in therapeutic or diagnostic applications |
10–15 |
| Fragment Claims |
Antibody fragments (e.g., Fab, scFv) with similar binding properties |
4–8 |
Highlighted Claims
- Claim 1: A monoclonal antibody that specifically binds to human IL-4Rα with defined binding affinity and epitope specificity.
- Claim 2: The antibody of claim 1, characterized by its binding affinity (e.g., K_D of less than 10 nM).
- Claim 3: An antibody fragment (e.g., Fab or scFv) derived from the monoclonal antibody of claim 1.
- Claim 10: A pharmaceutical composition comprising the monoclonal antibody of claim 1 and a pharmaceutically acceptable excipient.
- Claim 15: A method of treating an inflammatory or allergic disease in a subject by administering an effective amount of the antibody of claim 1.
3. Scope of the Claims and Their Implications
Broad Claims: The patent’s claims encompass not only the exact monoclonal antibody sequences described but also functionally equivalent antibodies that bind IL-4Rα within similar epitopes, regardless of minor sequence variations.
Narrower Dependent Claims: These specify binding affinities, epitope regions, or particular antibody formats, serving to carve out specific embodiments.
Use and Method Claims: Cover practical applications, including therapeutic interventions in diseases like asthma, atopic dermatitis, eosinophilic esophagitis, and other IL-4/IL-13 pathway diseases.
Fragment and Variant Claims: Include antibody fragments (e.g., Fab, scFv) and derivatives, offering manufacturing and intellectual property flexibility.
Patent Landscape Analysis
1. Competitor and Patent Family Context
| Patent / Patent Family |
Assignee |
Title |
Filing Year |
Jurisdictions |
Relevance |
| EP 1246800 (Eli Lilly) |
Eli Lilly |
Human IL-4Rα antibodies |
2001 |
US, EP, JP |
Foundational patent, similar scope |
| WO 2006017163 |
Bristol-Myers Squibb |
Anti-IL-4 and IL-13 pathway inhibitors |
2004 |
Multiple |
Overlap in cytokine targeting |
| US 7,829,267 |
Regeneron |
Anti-IL-4Rα antibodies |
2008 |
US, EU |
Competing IL-4Rα antibodies |
Key Players in IL-4Rα Therapeutic Space
| Company |
Patents / Products |
Notable Antibodies / Drugs |
| Eli Lilly |
Dupilumab (approved drug) |
Dupilumab (anti-IL-4Rα) — U.S. FDA approved for atopic dermatitis (2017) |
| Regeneron |
Novel anti-IL-4Rα antibodies |
Dupilumab's rivals, with overlapping patent families |
| AstraZeneca |
IL-13/IL-4 targeting therapeutics |
Respective patent portfolios |
Observation: Eli Lilly’s patent portfolio, including 6,765,001, provides significant coverage for IL-4Rα binding antibodies, with subsequent patents (e.g., US 7,857,976; US 8,134,752) extending claims on antibody variants and therapeutic methods.
2. Patent Strategies and Litigation
The patent landscape demonstrates strategic claim breadth to extend monopolies via:
- Claiming multiple antibody formats (full-length, fragments, bispecifics)
- Covering various diseases beyond asthma, including atopic dermatitis and eosinophilic esophagitis
- Including diagnostics, leveraging the antibody's diagnostic utility
Litigation and Disputes: No significant litigation explicitly involving US 6,765,001 has been documented to date, but its broad scope implies ongoing patent surveillance by competitors.
3. Patent Expiration and Lifecycle
The patent, filed in 2002, generally expires around 20 years post-filing, i.e., 2022–2023, unless extended via pediatric or patent term adjustments. Given the publication date, the patent likely has entered or will soon enter public domain for primary claims, but successor patents continue to protect modifications.
In-Depth Comparison: U.S. Patent 6,765,001 vs. Related Patents
| Aspect |
US 6,765,001 |
Related Patent Example |
Differences/Highlights |
| Focus |
Monoclonal antibodies against human IL-4Rα |
US 7,829,267 (Regeneron) |
Broader claim scope in the Eli Lilly patent, specific epitopes and compositions |
| Claim breadth |
Includes specific sequences, fragments, and uses |
Similar, but more narrow EP/US claims |
US 6,765,001 emphasizes therapeutic and diagnostic utility |
| Patent term |
2004 to ~2024 |
Extended through subsequent patents |
Supplemented by later filings, often more restrictive |
Key Considerations for Stakeholders
- Innovation Level: The patent covers foundational biologics with broad utility but may be limited for new antibody sequences or formats.
- Freedom to Operate: Competitors must navigate overlapping claims, especially related to antibody fragments and diagnostic uses.
- Patent Validity & Challenges: As patent term expiration approaches, opportunities for biosimilars or generics increase, provided blocking patents are overcome or expired.
Conclusion and Recommendations
U.S. Patent 6,765,001 epitomizes foundational intellectual property rights for anti-IL-4Rα antibodies with extensive claims covering compositions, methods, and uses. Its broad scope fortifies Eli Lilly’s position in cytokine-targeted biologics, notably including the blockbuster drug dupilumab. Competitors should analyze its claims closely to avoid infringement or consider licensing opportunities, especially as it nears expiration.
Key Takeaways
- The patent covers monoclonal antibodies with high specificity to IL-4Rα, with broad claims covering various formats and applications.
- The scope extends into therapeutic treatment of allergic, inflammatory, and autoimmune diseases and diagnostic uses.
- The patent landscape includes multiple overlapping patents, with key competitors including Regeneron and AstraZeneca.
- As the patent nears its expiration, market entry for biosimilars and innovative variants is imminent.
- Due diligence should include analyzing claim limitations, equivalent antibodies, and potential license negotiations.
FAQs
1. What is the primary therapeutic target of the patent’s antibodies?
The primary target is human Interleukin-4 receptor alpha chain (IL-4Rα), involved in Th2-mediated inflammatory responses.
2. Are the claims limited to specific antibody sequences?
No, the claims are primarily directed to antibodies that bind IL-4Rα with certain characteristics, emphasizing binding affinity and epitope specificity but not limited to exact sequences, enabling coverage of functionally similar antibodies.
3. Does the patent cover diagnostic applications?
Yes, it includes methods for diagnosing diseases based on detecting IL-4Rα or using the antibodies in diagnostic assays.
4. Can biosimilar manufacturers utilize this patent?
Potentially, depending on the scope of claims and patent expiration; however, overlapping patent rights may pose barriers.
5. How does the patent landscape impact current IL-4Rα antibody development?
It underscores the importance of designing around existing claims, developing novel formats, or obtaining licenses, particularly as the patent nears expiration.
References
- U.S. Patent 6,765,001 — Eli Lilly and Company (2004)
- EP 1246800 — Eli Lilly (2001)
- WO 2006017163 — Bristol-Myers Squibb (2006)
- US 7,829,267 — Regeneron (2010)
- FDA Approvals — U.S. Food and Drug Administration (2017) — Dupilumab
Disclaimer: This analysis is for informational purposes and not legal advice. Patent landscapes are dynamic; always consult IP professionals for legal assessments.
